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BACKGROUND AND PURPOSE
PZM21 is a novel μ-opioid receptor ligand that has been reported to induce minimal arrestin recruitment and be devoid of the
respiratory depressant effects characteristic of classical μ receptor ligands such as morphine. We have re-examined the signalling
proﬁle of PZM21 and its ability to depress respiration.
EXPERIMENTAL APPROACH
G protein (Gi) activation and arrestin-3 translocation were measured in vitro, using BRET assays, in HEK 293 cells expressing μ
receptors. Respiration (rate and tidal volume) was measured in awake, freely moving mice by whole-body plethysmography, and
antinociception was measured by the hot plate test.
KEY RESULTS
PZM21 (109 – 3 × 105 M) produced concentration-dependent Gi activation and arrestin-3 translocation. Comparison with
responses evoked by morphine and DAMGO revealed that PZM21 was a low efﬁcacy agonist in both signalling assays. PZM21
(10–80mg·kg1) depressed respiration in a dose-dependent manner. The respiratory depression was due to a decrease in the rate
of breathing not a decrease in tidal volume. On repeated daily administration of PZM21 (twice daily doses of 40 mg·kg1),
complete tolerance developed to the antinociceptive effect of PZM21 over 3 days but no tolerance developed to its respiratory
depressant effect.
CONCLUSION AND IMPLICATIONS
These data demonstrate that PZM21 is a low efﬁcacy μ receptor agonist for both G protein and arrestin signalling. Contrary to a
previous report, PZM21 depresses respiration in a manner similar to morphine, the classical opioid receptor agonist.
Abbreviations
DAMGO, D-Ala2, N-MePhe4, Gly-ol-enkephalin; GIRK, G protein-activated inwardly rectifying potassium channel; MPE,
maximum possible effect; MV, minute volume; PZM21, 1-[(2S)-2-(dimethylamino)-3-(4-hydroxyphenyl)propyl]-3-[(2S)-1-
(thiophen-3-yl)propan-2-yl]urea; Rluc, Renilla luciferase
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Introduction
Opioid-induced respiratory depression is the primary cause
of death following illicit or prescription opioid misuse.
Fatal opioid overdose accounted for over 140 deaths a
day in the USA in 2016 (National Institutes of Health).
In a signiﬁcant proportion of these deaths, a prescription
opioid or illicitly synthesized opioid, rather than heroin,
was involved. The development of an opioid agonist with
appreciable potency as an analgesic, but lacking the ability
to induce respiratory depression, would be highly desir-
able for clinical application and to reduce opioid-related
deaths.
Current therapeutically useful opioid ligands such as
morphine produce their analgesic and respiratory depres-
sant effects through activation of the μ-opioid receptor
(μ receptor) (Matthes et al., 1996). The μ receptor is a
GPCR that signals through activation of Gi/Go proteins
and through arrestin signalling (Williams et al., 2013). In re-
cent years, the concept of biased ligands for GPCRs has been
developed (Kelly, 2013; Kenakin and Christopoulos, 2013;
Thompson et al., 2015; Smith et al., 2018). It is now well
established that agonists acting at the same orthosteric site
on a GPCR may activate different signalling pathways, that
is, be biased for activating G protein or arrestin signalling.
The idea that a G protein-biased μ receptor agonist would
have a reduced ‘on target’ side effect proﬁle arises from the
observation that in arrestin-3 (β-arrestin 2) knockout mice,
morphine, the prototypical opioid agonist, showed a re-
duced propensity to produce respiratory depression and
constipation (Raehal et al., 2005) implying that respiratory
depression resulted from μ receptor coupling to arrestin-
mediated signalling.
Manglik et al. (2016) reported the development of a novel
μ receptor agonist, PZM21, structurally unrelated to proto-
typical μ receptor agonists such as morphine, which ap-
peared to have some selectivity for G protein activation
over arrestin translocation. They also reported that PZM21
had a greatly reduced propensity to produce respiratory de-
pression. We have synthesized PZM21 and have re-examined
its selectivity proﬁle for Gi activation over arrestin-3 recruit-
ment and its ability to depress respiration in mice. We ob-
served that PZM21 was a low efﬁcacy agonist for both Gi
activation and arrestin recruitment. In contrast to Manglik
et al. (2016), we observed that PZM21 signiﬁcantly depressed
respiration, in a manner similar to an equi-antinociceptive
dose of morphine.
Methods
Gi activation and arrestin-3 translocation assays. HEK 293
cells were cultured at 37°C in DMEM supplemented with
10% fetal bovine serum and penicillin/streptomycin. Cells
were seeded onto 10 cm dishes and grown to 80%
conﬂuence before transfection. To determine the relative
ability of the agonists to activate Gαi G proteins, a BRET
2-
based assay that monitors the separation of Gαi1 and Gγ2
was used. HEK 293 cells were transiently transfected with
rat HA-μ receptors, Gαi1-Renilla luciferase II (RlucII) and
GFP10-Gγ2. Immediately prior to each assay, cells were
resuspended in clear DMEM and then transferred to a 96-
well plate at 90 μL per well. Measurements of BRET were
made at 37°C. Coelenterazine 400a, at a ﬁnal
concentration of 5 μM, was injected 5 s prior to reading
the cell plate. BRET measurements were made on a
FLUOstar Omega plate reader (BMG LABTECH, Ortenberg,
Germany) using the following ﬁlter set: acceptor,
515 ± 30 nm; and donor, 410 ± 80 nm ﬁlters. BRET signals
were determined as the ratio of the light emitted by
acceptors (GFP10) over donor (RlucII). For Gi activation,
BRET measurements were taken 2 min after agonist
application. Agonist stimulation resulted in a rapid
decrease in the BRET signal between Gαi1-RlucII and
GFP10-Gγ2 in cells co-expressing the HA-tagged μ
receptors. To determine the extent of agonist-induced
arrestin-3 association, cells were co-transfected with
human μ receptor-Rluc and arrestin-3-GFP. The extent of
arrestin-3 recruitment to the receptor was assessed
following a 10 min incubation with the agonists.
Animals. All animal care and experimental procedures were
performed in accordance with the UK Animals (Scientiﬁc
Procedures) Act 1986, the European Communities Council
Directive (2010/63/EU) and the University of Bristol ethical
review document. Animal studies are reported in
compliance with the ARRIVE guidelines (Kilkenny et al.,
2010; McGrath and Lilley, 2015). Male C57BL and CD-1
mice (Harlan Laboratories, Bicester, UK) weighing approximately
30 g were group housed, four to six per cage, in an
environment maintained at 22°C, on a reversed 12 h
dark–light cycle with food and water available ad libitum.
Experiments were performed in the dark phase to ensure
that they were in their most active phase. Animals were
randomly ascribed to treatment groups with the experimenter
blinded to drug treatment until after subsequent data
analyses had been performed. A total of 180 mice were used
in the study.
Mouse respiration. We have used both C57BL mice, the
strain used by Manglik et al. (2016), and CD-1 mice, the
strain we have used in previous studies of opioid
depression of respiration (Hill et al., 2016; Lyndon et al.,
2017; Withey et al., 2017) to ensure that any responses
observed were not strain-speciﬁc. Respiration was measured
in freely moving mice using plethysmography chambers
(EMKA Technologies, Paris, France) supplied with either air
or a 5% CO2 in air mixture (BOC Gas Supplies,
Manchester, UK) as described previously (Hill et al., 2016).
Rate and volume of respiration were recorded and averaged
over 5 min periods. Breathing 5% CO2 in air increases
minute volume (MV) but does not induce stress in mice
(Hill et al., 2016).
Data are presented both as MV and as percentage change
from the pre-drug MV baseline, calculated for each mouse in-
dividually before mean data were plotted. Presenting data as
percentage change from the pre-drug levels has been done
to control for variation between treatment groups that may
have different baseline levels of respiration. In our experi-
ence, variations in baseline respiration levels do not
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inﬂuence the extent of opioid depression of respiration (Hill
and Henderson, unpublished data).
Measurement of nociception. Male mice (CD-1) were placed
on a hot plate at 52.5°C, and the latency to exhibit paw
withdrawal, jumping or paw licking was measured. A
maximum cut-off time of 30 s was used to prevent tissue
damage. Hot plate latency was measured every 15 min.
Antinociception was quantiﬁed as the percentage of
maximum possible effect (% MPE), which was calculated as
follows:
%MPE ¼ test latency control latencyð Þ½
= 30 control latencyð Þ100:
Induction of tolerance. Male mice (CD-1) received twice daily
injections (at 09:00 and 21:00 h each day) of PZM21,
morphine or saline at 12 h intervals for 5 days. Two separate
sets of experiments were performed, one to measure
tolerance to antinociception and the other to measure
tolerance to respiratory depression. Each day, hot plate
latency or respiration was monitored for 60 min after the
ﬁrst drug administration of the day.
Experimental design and data analysis
In vitro experiments. The maximum responses for PZM21,
DAMGO and morphine in both Gi activation and arrestin-3
recruitment were compared using one-way ANOVA with
Bonferroni’s post test.
In vivo experiments. Data from previous experiments where
respiratory depression or antinociception was measured
following acute opioid administration in naïve mice were
subjected to post hoc power analyses using G*Power (version
3.1.9). Our calculations indicated that n = 6 (respiration
experiments) or n = 8 (antinociception experiments) for
each individual group would produce a signiﬁcant result if
an actual effect occurred.
Differences between drug treatments and saline controls
over time were analysed using two-way ANOVA with
Bonferroni’s post test. Changes in groups over time with re-
peat measurements were analysed using two-way repeated
measures ANOVA with Bonferroni’s post test to analyse drug
effect over time. Statistical signiﬁcance and F (dfn, dfd) values
are given in the ﬁgure legends. GraphPad Prism 7was used for
all statistical analyses. All data are displayed as mean ± SEM.
The data and statistical analyses comply with the recommen-
dations on experimental design and analysis in pharmacol-
ogy (Curtis et al., 2015).
Materials. PZM21 hydrochloride was synthesized from
enantiopure (S)-1-(thiophen-3-yl)propan-2-amine and
enantiopure (S)-4-(3-amino-2-(dimethylamino)propyl)
phenol (both supplied by Astatech, Bristol, Pennsylvania).
The synthesis followed the methods reported by Manglik
et al. (2016). Analysis by NMR, mass spectrometry and HPLC
conﬁrmed identity and purity of the sample. Reverse phase
HPLC (Kinetix C18 column) and chiral analysis (Chiralpak
AS column) demonstrated it to be identical to a sample of S,S
PZM21 formate kindly provided by Dr Gmeiner (Friedrich-
Alexander-Universität, Erlangen-Nürnberg, Germany) and
conﬁrmed >98% of the desired isomer (S,S PZM21). Data
using both batches of PZM21 (i.e. those synthesized at the
University of Bath and at Friedrich-Alexander-Universität)
are reported in this paper.
DAMGO (Tocris Bioscience, Avonmouth, UK), morphine
hydrochloride (Macfarlan Smith, Edinburgh, UK), naloxone
hydrochloride (Sigma-Aldrich, Dorset, UK) and PZM21
hydrochloride were dissolved in deionized water (in vitro ex-
periments) or sterile saline (in vivo experiments). PZM21 for-
mate was dissolved in saline/1% DMSO. All doses of drug
were administered in 0.1 mL vehicle.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data
from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding
et al., 2018), and are permanently archived in the Concise
Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017).
Results
μ receptor signalling
In HEK 293 cells expressing μ receptors, PZM21 (109 –
3 × 105M) produced concentration-dependent Gi activation
(Figure 1A and Table 1). We compared the responses evoked
by PZM21 to those evoked by two well-characterized μ recep-
tor ligands, DAMGO (high efﬁcacy agonist) and morphine
(lower efﬁcacy agonist) in the same assay. Examination of
the maximum response produced by each agonist (an indica-
tion of agonist efﬁcacy) (Table 1) revealed that under our as-
say conditions, PZM21 and morphine were partial agonists
for Gi activation with signiﬁcantly lower efﬁcacy than
DAMGO.
In the arrestin-3 recruitment assay PZM21 (109
– 3 × 105 M) produced a small but measurable amount of
arrestin recruitment (Figure 1B). The maximum responses to
PZM21 and morphine were lower than that of DAMGO
whereas PZM21 and morphine were not signiﬁcantly
different.
Acute antinociception and respiratory
depression
In the mouse (CD-1) hot plate assay PZM21 (40 mg·kg1 i.p.)
increased latency for nociceptive behaviour for the duration
of the 60 min observation period following drug administra-
tion (Figure 2A). The peak antinociceptive response induced
by PZM21 (40 mg·kg1 i.p.) was similar to that induced by
morphine (10 mg·kg1 i.p.) when compared by two-way
ANOVA with Bonferroni’s comparison [F = 1.65 (dfn = 1,
dfd = 98) P > 0.05] (Figures 2A and 5A).
In contrast to Manglik et al. (2016), we observed that in
C57/BL mice breathing air PZM21 (40 mg·kg1 injected s.c.)
caused signiﬁcant respiratory depression (Figure 2B) that
was rapid in onset, the peak effect being attained
10 – 15 min after injecting the drug, and persisted for the
duration of the 30 min post injection observation period.
PZM21 depresses respiration
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The decrease in MV caused by 40 mg·kg1 PZM21 was sim-
ilar in amplitude to that observed following administration
of 10 mg·kg1 morphine (Figure 2B). To conﬁrm that the re-
spiratory depressant effect of PZM21 that we had observed
was not due to the presence of any impurity, we obtained a
sample of PZM21 from Dr Peter Gmeiner who synthesized
the PZM21 used in the Manglik et al. (2016) study; we
observed that 40 mg·kg1 (i.p.) of this sample of PZM21 also
depressed respiration (Figure 2C).
In mice breathing air, respiration gradually declines with
time (see data for saline or saline/1% DMSO-treated mice in
Figure 2B, C and for vehicle-injected mice in ﬁgure 4g in
Manglik et al., 2016); animals also sometimes curl up ‘asleep’
which interferes with plethysmograph recording. To circum-
vent this, we performed experiments in which mice breathe
5% CO2 in air (see Hill et al., 2016; Withey et al., 2017). This
increases MV, which in saline-treated mice remains constant
for periods of up to 90 min (Figure 2D). In CD-1 mice breath-
ing 5% CO2 in air, the respiratory depression induced by
Figure 1
Opioid-induced Gi protein activation and arrestin-3 translocation in
HEK 293 cells expressing recombinant μ receptors. (A) DAMGO,
morphine and PZM21 induced concentration-dependent activation
of Gi measured as the decrease in BRET signal. (B) DAMGO, mor-
phine and PZM21 induced concentration-dependent arrestin-3
translocation measured as the increase in BRET signal. Values of
EC50 and maximum response are recorded in Table 1. Data shown
are means ± SEM, N = 5 for each drug in both assays.
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PZM21 (10 – 40 mg·kg1 i.p.) was dose-dependent and was
maintained over the 60 min period following drug adminis-
tration (Figure 2D, E). Over the range of doses tested,
PZM21 was approximately fourfold less potent than mor-
phine (Figure 2E).
The decrease inMV in response to PZM21 or morphine re-
sulted from a decrease in respiratory rate rather than a de-
crease in tidal volume (Figure 3). Although the depth of
respiration was reduced, tidal volume was maintained be-
cause the duration of inspiration was prolonged by an
apneustic compensation (see also Hill et al., 2016).
Administration of naloxone (1 mg·kg1 i.p.) along with
PZM21 (40mg·kg1 i.p.) prevented the respiratory depression
induced by PZM21 (Figure 4A), demonstrating that this effect
of PZM21 was mediated by opioid receptor activation. How-
ever, when the dose of PZM21 was increased to 80 mg·kg1
(i.p.), the degree of respiratory depression also increased,
but in this instance, the effect of PZM21 was not fully re-
versed even by a higher dose of naloxone (3 mg·kg1 i.p.)
(Figure 4B). This indicates that at high doses, the respiratory
depression by PZM21 may involve a non-opioid receptor-
mediated component.
Figure 2
Antinociception and respiratory depression induced by PZM21 and morphine in mice. (A) PZM21 (40 mg·kg1 i.p.) and morphine
(10 mg·kg1 i.p.) enhanced paw withdrawal latency in the mouse (CD-1) hot plate antinociception test [withdrawal latencies for both PZM21- and
morphine-treatedmicewere statistically different from those in saline-treatedmiceat all timepoints followingdrug injection; F = 43.53 (dfn =2, dfd=147)
P< 0.05]. (B) PZM21 (40 mg·kg1 s.c.) and morphine (10 mg·kg1 s.c.) depressed respiration, measured as MV, in C57/BL mice breathing air. (C) A
separately synthesized sample of PZM21 (40 mg·kg1 i.p.) supplied by Dr Peter Gmeiner also depressed respiration in C57/BL mice breathing air.
(D) PZM21 (40 mg·kg1 i.p.) and morphine (10 mg·kg1 i.p.) depressed respiration in CD-1 mice breathing 5% CO2 in air for a period of
100 min post drug injection. In (B), the extent of respiratory depression induced by either PZM21 or morphine was statistically different from
saline-treated mice at 5 – 45 min post drug injection [F = 36.77 (dfn = 2, dfd = 165) P < 0.05] whereas in (C), statistical difference was observed at
all time points 10 min post drug injection [F = 115.88 (dfn = 1, dfd = 110) P < 0.05] (asterisks to denote statistical signiﬁcance are omitted from
the ﬁgure to maintain clarity). In (D), the extent of respiratory depression induced by either PZM21 or morphine was statistically different from
saline-treated mice at 10–100 min time points following drug injection [F = 418.15 (dfn = 2, dfd = 315) P < 0.05]. (E) PZM21 (10–40 mg·kg1 i.p.)
and morphine (1–30 mg·kg1 i.p.) depressed respiration in CD-1 mice breathing 5% CO2 in air in a dose-dependent manner. Percent respiratory
depression has been calculated for eachmouse at the peak effect of the drugs which for all doses occurred at 10 or 15min after injection. In (A–E), data
shown are means ± SEM (N = 6 for all groups). Data were analysed by two-way ANOVA with Bonferroni’s post test.
PZM21 depresses respiration
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Differential development of tolerance to
antinociception and respiratory depression by
PZM21
We have previously used a twice daily injection of opioid to
study the development of tolerance to the antinociceptive
(tail ﬂick test) and respiratory depressant effects of morphine
and observed that tolerance developed to the antinociceptive
action of morphine but not to the respiratory depressant ac-
tion (Hill et al., 2016). Here, we utilized a similar twice daily
opioid injection protocol in which mice were injected at
09:00 and 21:00 h each day with PZM21 (40 mg·kg1 i.p.) or
morphine (10 mg·kg1 i.p.) for up to 5 days.
Repeated injection of PZM21 or morphine resulted in the
development of tolerance to their antinociceptive effects as
measured in the hot plate assay (Figure 5A). By the fourth
day of treatment, PZM21 and morphine did not induce any
antinociception. In a separate group of mice, we observed
that tolerance to the respiratory depressant effect of PZM21
did not develop even after 5 days of treatment (Figure 5B).
For comparison with morphine, data showing lack of toler-
ance development to respiratory depression with repeated
morphine dosing have been recalculated from Hill et al.
(2016) and included in Figure 5B.
Discussion
The main ﬁnding of this study is that the structurally novel μ
receptor agonist PZM21 induces marked respiratory depres-
sion, similar to morphine. This ﬁnding is at odds with a
previous study where PZM21 was reported not to induce re-
spiratory depression (Manglik et al., 2016). In addition to
our ﬁndings with the sample of PZM21 that we synthesized,
we also obtained a sample of PZM21 from the original inves-
tigators and still observed respiratory depression with that
sample. We observed respiratory depression in both C57BL
and CD-1 mice showing that the response is not strain spe-
ciﬁc. Furthermore, we observed respiratory depression when
PZM21 was injected i.p. or s.c. and when animals breathed
air or 5% CO2 in air to stabilize respiration across the observa-
tion period. We did not observe depression of respiration
when mice were injected with vehicle alone. This is in con-
trast to Manglik et al. (2016) who observed a large effect in
vehicle-injected mice that may have obscured the respiratory
depressant effect of PZM21.
We have also demonstrated that repeated administration
of PZM21 induced tolerance to its antinociceptive effect, sim-
ilar to that seen with morphine, but with this treatment
schedule, PZM21 did not induce tolerance to respiratory de-
pression, again as seen with morphine.
PZM21 is a low efﬁcacy agonist for both G protein and
arrestin signalling. The maximum response to PZM21 com-
pared to that of DAMGO does appear to be lower for
arrestin-3 translocation than for Gi activation (compare
Figures 1A, B). This could indicate that PZM21 exhibits some
bias for Gi activation over arrestin-3 translocation. However,
with low efﬁcacy agonists such as PZM21, the error in EC50
values obtained from the concentration–response curves is
large (see Table 1) which makes conclusions about bias difﬁ-
cult. The problems of quantifying bias with low efﬁcacy
Figure 3
PZM21 and morphine depress respiratory rate not tidal volume. (A) and (B) show raw respiration traces recorded from a single CD-1 mouse
breathing 5% CO2 in air before (A) and after (B) administration of PZM21 (40 mg·kg
1 i.p.). The horizontal line indicates the point of pressure
inﬂexion. On the respiration traces, inspiration is downwards. (C, D) In mice breathing 5% CO2 in air, PZM21 (40 mg·kg
1 i.p.) and morphine
(10 mg·kg1 i.p.) have no effect on tidal volume [F = 15.37 (dfn = 2, dfd = 315) P > 0.05] but reduce the rate of respiration at all time points
following drug injection (morphine) and reduce the rate of respiration at 25 – 70, 85 and 95 – 100 min (PZM21) [F = 187,27 (dfn = 2, dfd = 110)
P < 0.05]. Data shown are means ± SEM (N = 6 in all groups) and were analysed by two-way ANOVA with Bonferroni’s post test.
R Hill et al.
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agonists and comparing bias between different cell types and
assays are increasingly being acknowledged (Thompson et al.,
2015; Winpenny et al., 2016; Michel and Charlton, 2018). It
should be noted that in Manglik et al. (2016), the authors
were unable to formally demonstrate that PZM21 was G
protein-biased, even in the presence of overexpressed
GRK2 to amplify the arrestin response.
In the present study, PZM21 did produce
antinociception in the hot plate assay, but contrary to the
previous report on this drug (Manglik et al., 2016), we also
observed that PZM21 produced prolonged respiratory
depression. PZM21 is therefore very similar to the proto-
typic opioid morphine, although in vivo it is less potent.
While the current dogma is that, for μ receptor agonists, re-
spiratory depression results from activation of arrestin sig-
nalling (see Chan et al., 2017; Madariaga-Mazón et al.,
2017; Roth et al., 2017; Smith et al., 2018), there is evidence
that signalling through Gi/Go is also involved in mediating
this behaviour. μ Receptor coupling through Gi/Go proteins
results in activation of G protein-activated inwardly
rectifying potassium channels (GIRKs) and inhibition
of voltage-gated calcium channels (North and Williams,
1985; Seward et al., 1991), and it has been reported that
the respiratory depression induced by either DAMGO,
Figure 4
Naloxone reversal of respiratory depression induced by PZM21. (A)
Treatment with naloxone (1 mg·kg1 i.p.; NLX) at the same time as
PZM21 injection prevented the respiratory depression in CD-1 mice
induced by PZM21 (40 mg·kg1). Respiratory depression following
PZM21 injection was signiﬁcantly less in naloxone-treated mice than
in saline-treated mice at all time points following drug injection
[F = 76.63 (dfn = 1, dfd = 80) P < 0.05]. (B) In contrast, the respira-
tory depression induced by PZM21 (80 mg·kg1 i.p.) in CD-1 mice
was not reversed by a higher dose of naloxone (3 mg·kg1 i.p.)
[F = 8.58 (dfn = 1, dfd = 110) P> 0.05]. Data shown are means ± SEM
(N = 6 in all groups) and were analysed by two-way ANOVA with
Bonferroni’s post test.
Figure 5
Repeated injection of PZM21 or morphine induced tolerance to their
antinociceptive effect but not to their respiratory depressant effect.
(A). Antinociceptive responses to the ﬁrst injection of PZM21 (40-
mg·kg1), morphine (10 mg·kg1) or saline on each day in mice
(CD-1) receiving twice daily doses of either drug for 4 days. Data
shown are means± SEM (N = 8 in all groups) of the maximum in-
crease in hot plate latency (% MPE) after administering the drug.
For both PZM21 and morphine, there was a progressive reduction
in response on days 2–4 [F = 8.56 (dfn = 6, dfd = 63) P < 0.05]. Data
in (A) have been analysed by two-way repeated measures ANOVA.
(B) Maximum respiratory depression in response to the ﬁrst injection
of PZM21 (40 mg·kg1), morphine (10 mg·kg1) or saline on each
day in mice (CD-1) receiving twice daily doses of drug for 5 days.
Data shown are means± SEM (N = 6 in both groups). The data for
morphine are recalculated from ﬁgure 2e of Hill et al. (2016). There
was no reduction in the respiratory depressant effect of PZM21 or
morphine over 5 days of drug administration [F = 0.83 (dfn = 8, dfd-
= 110) P> 0.05]. Data in (A) and (B) have been analysed by two-way
repeated measures ANOVA with Bonferroni’s post test.
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applied locally in the ventrolateral medulla, or fentanyl,
administered systemically, is attenuated in GIRK2 subunit
knockout mice (Montandon et al., 2016). The effect of
DAMGO on respiration was also reduced in wild-type
mice by local administration of Tertiapin-Q, a blocker
of GIRK channels. This would imply that respiratory de-
pression involves μ receptors coupling to GIRK channels
through activation of Gi/Go proteins. Furthermore, the
role of Gi/Go-coupling to voltage-dependent calcium
channels in respiratory depression has not been evalu-
ated. On the other hand, morphine-induced respiratory
depression was reported to be reduced in arrestin-3
knockout mice (Raehal et al., 2005), while Schmid et al.
(2017) have recently described several novel G protein-
biased μ receptor ligands that appear to induce less respi-
ratory depression than morphine at equi-antinociceptive
doses. Nevertheless, our present results with PZM21 ques-
tion the assumption that arrestin-dependent signalling
mediates the respiratory depression observed with μ recep-
tor agonists.
We observed that on repeated administration, tolerance
developed to the antinociceptive effect of PZM21, as has
previously been widely reported with morphine (see refer-
ences in Williams et al., 2013). This ﬁnding suggests that
the evasion of tolerance to the analgesic effects, a suggested
beneﬁt of G protein-preferring μ receptor agonists (Smith
et al., 2018), is not achieved and that instead such agonists
remain able to trigger signalling mechanisms that lead to
profound tolerance. On the other hand, with twice daily in-
jections tolerance did not develop to the respiratory depres-
sant effect of PZM21. We have previously reported similar
differential tolerance development to morphine (Hill et al.,
2016). With morphine, more sustained drug delivery using
subcutaneous pellet or osmotic mini-pump implantation
did result in the development of tolerance to respiratory de-
pression but at a slower rate than tolerance to
antinociception (Hill et al., 2016; Withey et al., 2017). Un-
fortunately, we had insufﬁcient supplies of PZM21 to per-
form further experiments with osmotic mini-pump
delivery. The molecular mechanisms underlying the devel-
opment of tolerance to μ receptor agonists, particularly
lower efﬁcacy agonists that have lower propensity for
arrestin recruitment, are complex and contentious (see
Williams et al., 2013). Future studies should address the
mechanism(s) underlying tolerance induced by prolonged
PZM21 treatment.
Conclusions
In conclusion, our data on respiratory depression are in di-
rect contrast to the previously published observation by
Manglik et al. (2016) that PZM21 did not cause respiratory
depression in mice. Given that PZM21 did induce some
arrestin-3 translocation as well as Gi activation, we are un-
able to conclude deﬁnitively that, for μ receptor agonists, re-
spiratory depression is mediated by G protein or arrestin
signalling. The future identiﬁcation of higher efﬁcacy μ re-
ceptor agonists showing greater bias for G protein over
arrestin signalling remains a promising avenue for the de-
velopment of novel opioid agonists and should answer this
important question.
Acknowledgements
We thank Dr Michel Bouvier (University of Montreal,
Montreal, Canada) for the gift of the G protein BRET
constructs (NB. Domain Therapeutics is the holder of the
licence for all commercial use of the constructs), Dr Tomasso
Costa (Istituto Superiore di Sanità, Rome, Italy) for the gift
of the μ receptor luciferase and arrestin-3 GFP constructs
and Dr Peter Gmeiner (Friedrich-Alexander-Universität,
Erlangen-Nürnberg, Germany) for providing a small sample
of PZM21.
The work described in this paper was supported by the
following grants: NIH (RO1DA036975) to W.L.D. and G.H.;
NIH (RO1DA07315) to S.M.H.; andMedical Research Council
(MR/N020669/1) to E.P.K. The funders of the study had no
role in the study design, data collection, data analysis, data
interpretation or writing of the report.
Author contributions
R.H. performed the in vivo respiration and antinociception
experiments, analysed the data and prepared the ﬁgures.
A.D. and S.H. synthesized PZM21. A.C. and K.S. performed
the in vitro BRET experiments and analysed the data. W.D.,
C.B., E.K. and G.H. conceived the study and wrote the paper.
All authors revised the manuscript.
Conﬂict of interest
The authors declare no conﬂicts of interest.
Declaration of transparency and
scientiﬁc rigour
This Declaration acknowledges that this paper adheres to the
principles for transparent reporting and scientiﬁc rigour of
preclinical research recommended by funding agencies, pub-
lishers and other organisations engaged with supporting
research.
References
Alexander SPH, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding
SD et al. (2017). The Concise Guide to Pharmacology 2017/18: G
protein-coupled receptors. Br J Pharmacol 174 (Suppl 1): S17–S129.
Chan HCS, McCarthy D, Li J, Palczewski K, Yuan S (2017). Designing
Safer Analgesics via μ-Opioid Receptor Pathways. Trends Pharmacol
Sci 38: 1016–1037.
Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz
MA et al. (2015). Experimental design and analysis and their
reporting: new guidance for publication in BJP. Br J Pharmacol 172:
3461–3471.
Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S
et al. (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018:
R Hill et al.
2660 British Journal of Pharmacology (2018) 175 2653–2661
updates and expansion to encompass the new guide to
IMMUNOPHARMACOLOGY. Nucl Acids Res 46: D1091–D1106.
Hill R, Lyndon A, Withey S, Roberts J, Kershaw Y, Maclachlan J et al.
(2016). Ethanol reversal of tolerance to the respiratory depressant
effects of morphine. Neuropsychopharmacology 41: 762–773.
Kelly E (2013). Efﬁcacy and ligand bias at the μ-opioid receptor. Br J
Pharmacol 169: 1430–1446.
Kenakin T, Christopoulos A (2013). Signalling bias in new drug
discovery: detection, quantiﬁcation and therapeutic impact. Nat Rev
Drug Discov 12: 205–216.
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010).
Animal research: reporting in vivo experiments: the ARRIVE
guidelines. Br J Pharmacol 160: 1577–1579.
Lyndon A, Audrey S, Wells C, Burnell ES, Ingle S, Hill R et al. (2017).
Risk to heroin users of polydrug use of pregabalin or gabapentin.
Addiction 112: 1580–1589.
Madariaga-Mazón A, Marmolejo-Valencia AF, Li Y, Toll L, Houghten
RA, Martinez-Mayorga K (2017). μ-opioid receptor biased ligands: a
safer and painless discovery of analgesics? Drug Discov Today 22:
1719–1729.
Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G et al.
(2016). Structure-based discovery of opioid analgesics with reduced
side effects. Nature 537: 185–190.
Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S,
Kitchen I et al. (1996). Loss of morphine induced analgesia, reward
effect and withdrawal symptoms in mice lacking the μ-opioid
receptor gene. Nature 383: 819–823.
McGrath JC, Lilley E (2015). Implementing guidelines on reporting
research using animals (ARRIVE etc.): new requirements for
publication in BJP. Br J Pharmacol 172: 3189–3193.
Michel MC, Charlton SJ (2018). Biased agonism in drug discovery – is
it too soon to choose a path? Mol Pharmacol 93: 259–265.
Montandon G, Ren J, Victoria NC, Liu H, Wickman K, Greer JJ et al.
(2016). G-protein-gated inwardly rectifying potassium channels
modulate respiratory depression by opioids. Anesthesiology 124:
641–650.
North RA, Williams JT (1985). On the potassium conductance
increased by opioids in rat locus coeruleus neurones. J Physiol 364:
265–280.
National Institutes of Health (National Institute on Drug Abuse)
Overdose death rates. Available at https://www.drugabuse.gov/related-
topics/trends-statistics/overdose-death-rates (accessed 27/4/2018).
Raehal KM, Walker JK, Bohn LM (2005). Morphine side effects in
β-arrestin 2 knockout mice. J Pharmacol Exp Ther 314: 1195–1201.
Roth BL, Irwin JJ, Shoichet BK (2017). Discovery of new GPCR ligands
to illuminate new biology. Nat Chem Biol 13: 1143–1151.
Schmid CL, Kennedy NM, Ross NC, Lovell KM, Yue Z, Morgenweck J
et al. (2017). Bias factor and therapeutic window correlate to predict
safer opioid analgesics. Cell 171: 1165–1175.
Smith JS, Lefkowitz RJ, Rajagopal S (2018). Biased signalling: from
simple switches to allosteric microprocessors. Nat Rev Drug Discov
17: 243–260.
Seward E, Hammond C, Henderson G (1991). μ-Opioid receptor-
mediated inhibition of the N-type calcium-channel current. Proc Roy
Soc Biol Sci 244: 129–135.
Thompson GL, Kelly E, Christopoulos A, Canals M (2015). Novel
GPCR paradigms at the μ-opioid receptor. Br J Pharmacol 172:
287–296.
Williams JT, Ingram SL, Henderson G, Chavkin C, Von Zastrow M,
Schulz S et al. (2013). Regulation of μ-opioid receptors:
desensitization, phosphorylation, internalization, and tolerance.
Pharmacol Rev 65: 223–254.
Winpenny D, ClarkM, Cawkill D (2016). Biased ligand quantiﬁcation
in drug discovery: from theory to high throughput screening to
identify new biased μ opioid receptor agonists. Brit J Pharmacol 173:
1393–1403.
Withey SL, Hill R, Lyndon A, Dewey WL, Kelly E, Henderson G
(2017). Effect of tamoxifen and brain-penetrantprotein kinase C
and c-Jun N-terminal kinase inhibitors on tolerance to opioid-
induced respiratory depression in mice. J Pharmacol Exp Ther
361: 51–59.
PZM21 depresses respiration
British Journal of Pharmacology (2018) 175 2653–2661 2661
